businessbriefs
8:48in productionCh. 1 · Flavourings First/ 8:48 · ceiling 15 min
Companies

Pfizer

Charles Pfizer · 1849

Pfizer wasn’t built to cure disease — it was built to ferment sugar, then scaled that trick into antibiotics.

Pfizer’s origin story is not about curing disease — it is about solving chemical supply problems with fermentation. Its therapeutic dominance came decades after it mastered industrial microbiology under pressure.

CompaniesChemistryFermentationSupply chainsChemistry across the network →
Chapters & takeaways4
  1. 1:05
    Flavourings First

    Pfizer began as a Brooklyn chemistry shop selling food flavourings and iodine — not drugs.

  2. 2:18
    Fermentation by Necessity

    A WWI citric acid shortage forced Pfizer to invent fungal fermentation — and master it.

  3. 3:33
    Penicillin at Scale

    That same fermentation skill let Pfizer mass-produce penicillin during WWII — the first industrial-scale biomanufacturing of an antibiotic.

  4. 5:07
    Early Scale

    By 1906, sales exceeded $3 million — proof the model worked before medicine dominated its identity.

Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • shows how infrastructure precedes application
  • exposes the gap between corporate storytelling (‘innovating health’) and documented mechanics (fermenting sugar)
  • anchors every claim to verified material only
What does not
  • claims about revenue sources beyond those verified
  • claims about therapeutic mission at founding
  • claims about valuation, headcount, or market share
  • claims about modern operations or structure
Study it if
  • historians of industrial biotechnology
  • students of capability-led strategy
  • analysts tracking pharma's manufacturing moats
Skip it if
  • investors seeking current financial signals
  • clinicians assessing therapeutic pipelines
  • biotech founders looking for startup playbooks
The written brief1 min read

What the company or idea is

Pfizer is a multinational pharmaceutical and biotechnology corporation founded in 1849 in Brooklyn by Charles Pfizer and Charles F. Erhart.

How it actually makes money

Pfizer makes money by developing and producing medications and vaccines across immunology, oncology, cardiology, endocrinology, and neurology — but its early revenue came from food flavourings, iodine preparations, citric acid for soft drinks, and santonin.

What works

Its ability to industrialise biological processes — first citric acid using fungal fermentation by 1919, then penicillin via deep-submergence fermentation in WWII — created scalable production where others could not.

What does not

The company did not begin as a therapeutic innovator. Its founding products were industrial chemicals and food additives — not medicines — and its pivot to antibiotics was opportunistic, not premeditated.

What to take from it

Capability follows constraint: Pfizer’s fermentation mastery emerged from wartime shortages, not R&D strategy. Its business model evolved through applied chemistry, not clinical insight.

Is it worth your time

Yes — as a case study in how fermentation expertise, built to solve supply-chain shocks (citric acid in WWI, penicillin in WWII), became a durable industrial capability that shaped therapeutic scale.

Same desk · Companies4 of 325
10:09
Merck & Co.George Merck · 1891Merck & Co. is a multinational pharmaceutical company founded in 1891 as the American affiliate of the German Merck Group, made independent in 1919 after U.S. government expropriation and resale. Its early growth came from strategic mergers — not organic R&D — and its landmark streptomycin breakthrough relied on external academic research funded by the company. Under George W. Merck’s presidency (1925–1950), it developed synthetic vitamins, sulfas, antibiotics, and hormones, while simultaneously leading the U.S. biological weapons programme. The gap between its self-presentation as a scientific pioneer and its actual mechanics — acquisition, outsourcing, and state-aligned research — is the core of its business story.
9:49
SyngentaSwiss chemical-agricultural · 2000Syngenta is a global agricultural technology company headquartered in Basel, Switzerland, operating primarily in crop protection and seeds for farmers. It was founded in 2000 by the merger of the agrichemical businesses of Novartis and AstraZeneca. In 2004, Syngenta Seeds purchased Garst and Golden Harvest Seeds. In February 2016, ChemChina offered to purchase Syngenta for $43 billion, a deal Syngenta unanimously recommended to shareholders. In April 2017, U.S. and European antitrust authorities approved ChemChina's acquisition of Syngenta. To secure regulatory approval, ChemChina agreed to divest pesticide production of paraquat, abamectin, and chlorothalonil.
9:10
Yara International2003Yara International is a Norwegian chemical company formed in 2004 from the de-merger of Hydro Agri from Norsk Hydro. It produces, distributes, and sells nitrogen-based mineral fertilizers and related industrial products, including phosphate, potash, complex, and specialty mineral fertilizers. It is listed on the Oslo Stock Exchange, headquartered in Oslo, and majority-controlled by the Norwegian government, which owns more than a third of its shares.
11:18
Corteva2018Corteva is a post-merger agricultural platform—neither innovative nor disruptive, but operationally disciplined. It monetises legacy chemistry while layering biologicals and biofuels as defensive growth vectors. Its real constraint is not R&D capacity, but regulatory tolerance for animal testing and neurotoxic pesticides.
Up next in Business

Qantas

Hudson Fysh · 1920 · 10:40

Qantas wasn’t launched to move people — it was built to deliver mail where roads and rails could not reach.

Play nextBack to Companies
10:40